This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.

开始日期2021-08-13

申办/合作机构

Neurotech Pharmaceuticals, Inc.

[+1]

NCT04577300 / Recruiting临床2期IIT

A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

开始日期2021-05-15

申办/合作机构

Stanford University

EUCTR2017-003260-12-DE / Unknown status临床3期

A Phase 3 Multicenter Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia type 2 - NTMT-03-B

开始日期2018-10-02

申办/合作机构

Neurotech Pharmaceuticals Inc.

100 项与 NT-501 相关的临床结果

登录后查看更多信息

100 项与 NT-501 相关的转化医学

登录后查看更多信息

100 项与 NT-501 相关的专利（医药）

登录后查看更多信息

项与 NT-501 相关的文献（医药）

2023-09-01·Ophthalmology science

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement.

Article

作者: Satterfield, Kellie R ; Lam, Byron L ; Albini, Thomas A ; Nuñez, Mariana ; Beykin, Gala ; Goldberg, Jeffrey L

Purpose:

To assess the safety and efficacy of a ciliary neurotrophic factor (CNTF) intraocular implant on neuroprotection and neuroenhancement in glaucoma.

Design:

Open-label, prospective, phase I clinical trial.

Participants:

A total of 11 participants were diagnosed with primary open-angle glaucoma (POAG). One eye of each patient was assigned as the study (implant) eye.

Methods:

The study eye was implanted with a high-dose CNTF-secreting NT-501 implant, whereas the other eye served as a control. All patients were followed up for 18 months. Analysis was limited to descriptive statistics.

Main Outcome Measures:

Primary outcome was safety through 18 months after implantation assessed by serial eye examinations, structural and functional testing, and adverse events (AEs) recording. Parameters measured included visual acuity (VA), Humphrey visual field (HVF), pattern electroretinogram, scanning laser polarimetry with variable corneal compensation (GDx VCC), and OCT. These parameters were also used for secondary analysis of efficacy outcome.

Results:

All NT-501 implants were well tolerated with no serious AEs associated with the implant. The majority of AEs were related to the implant placement procedure and were resolved by 12 weeks after surgery. Foreign-body sensation was the most commonly reported AE and was self-limited to the postoperative period. The most common implant-related AE was pupil miosis; no patients underwent explant. Visual acuity and contrast sensitivity decreased more in fellow eyes than in study eyes (VA, -5.82 vs. -0.82 letters; and contrast sensitivity, -1.82 vs. -0.37 letters, for fellow vs. study eyes, respectively). The median HVF visual field index and mean deviation measurements worsened (decreased) in fellow eyes (-13.0%, -3.9 dB) and improved (increased) in study eyes (2.7%, 1.2 dB). Implanted eyes showed an increase in retinal nerve fiber layer thickness measured by OCT and by GDx VCC (OCT, 2.66 μm vs. 10.16 μm; and GDx VCC, 1.58 μm vs. 8.36 μm in fellow vs. study eyes, respectively).

Conclusions:

The NT-501 CNTF implant was safe and well tolerated in eyes with POAG. Eyes with the implant demonstrated both structural and functional improvements suggesting biological activity, supporting the premise for a randomized phase II clinical trial of single and dual NT-501 CNTF implants in patients with POAG, which is now underway.

Financial Disclosures:

Proprietary or commercial disclosure may be found after the references.

2021-03-01·Veterinary ophthalmology4区 · 农林科学

Medical anti‐glaucoma therapy: Beyond the drop

4区 · 农林科学

Review

作者: Miller, Paul E. ; Eaton, Joshua Seth

Abstract:

Barriers to effective medical therapy are numerous and include difficulties with effective and sustained control of intraocular pressure (IOP) and adherence to prescribed anti‐glaucoma drop regimens. In an effort to circumvent these challenges, a number of new anti‐glaucoma therapies with sustained effects have emerged. Methods for sustained delivery of prostaglandin analogs are being intensely investigated and many are in human clinical trials. Intracameral devices include the following: Allergan's Durysta™ Bimatoprost SR, Envisia Therapeutics’ ENV515 travoprost implant, Glaukos’ iDose™, Ocular Therapeutix's OTX‐TIC travoprost implant, and Santen's polycaprolactone implant with PGE2‐derivative DE‐117. Other prostaglandin‐based technologies include Allergan's bimatoprost ring (placed in the conjunctival fornix), Ocular Therapeutics’ OTX‐TP intracanalicular travoprost implant, subconjunctival latanoprost in a liposomal formulation, and the PGE2 derivative PGN 9856‐isopropyl ester that is applied to the periorbital skin. Exciting breakthroughs in gene therapy include using viral vectors to correct defective genes such as MYOC or to modulate gonioimplant fibrosis, CRISPR technology to edit MYOC or to alter aquaporin to reduce aqueous humor production, and siRNA technology to silence specific genes. Stem cell technology can repopulate depleted tissues or, in the case of Neurotech's Renexus® NT‐501 intravitreal implant, serve as a living drug delivery device that continuously secretes neurotrophic factors. Other unique approaches involve nanotechnology, nasal sprays that deliver drug directly to the optic nerve and noninvasive alternating current stimulation of surviving cells in the optic nerve. Over time these modalities are likely to challenge the preeminent role that drops currently play in the medical treatment of glaucoma in animals.

2021-01-01·Ophthalmic research4区 · 医学

The Use of Neuroprotective Agents in Treating Geographic Atrophy

4区 · 医学

Review

作者: Giani, Andrea ; Scholl, Hendrik P N ; Chong, Victor ; Boyer, David

Geographic atrophy (GA) secondary to age-related macular degeneration accounts for close to one-quarter of cases of legal blindness in the USA and the UK. Despite this notable disease burden, the pathophysiology of GA is complex and not fully understood, and there is currently no approved treatment to prevent or slow its progression. GA is heterogeneous in its appearance and extent, and underlying associated traits such as drusen and complement factor polymorphisms vary between patients and by ethnicity, posing a challenge for treatment development. The root cause of vision loss in GA is photoreceptor death; therefore, protecting photoreceptors from damage and delaying their degeneration are key to successful GA treatment. There are multiple neuroprotective pathways that may contribute to protecting photoreceptors from damage, and compounds that target these pathways include antioxidants, neurotrophic factors, and catalases. However, the efficacy of previously trialled neuroprotective therapies in GA, such as brimonidine, tandospirone, and NT-501, has been inconsistent; this may be due to their target of action, method of delivery, and/or suboptimal duration of action. Neurotrophic factors, or molecules involved in neuroprotective signalling cascades, may be ideal agents for further investigation for the treatment of GA. Future neuroprotective strategies in GA must focus on the development of agents with a long duration of action that can combat the progression of chronic damage in GA to provide clinically meaningful benefits for patients.

项与 NT-501 相关的新闻（医药）

2023-09-13

·BioSpace

Alex Gorsky Joins Neurotech’s Board as Lead Director

CUMBERLAND, R.I.--(BUSINESS WIRE)-- Neurotech Pharmaceuticals, Inc., a private clinical stage biotech company, announced today that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Gorsky is the former Chairman and CEO of Johnson & Johnson. This press release features multimedia. View the full release here: Alex Gorsky (Photo: Business Wire) Under Gorsky’s leadership, Johnson & Johnson grew to become the world’s largest diversified healthcare company and one of the foremost innovators in research and development for emerging health technologies. His influence has shaped both the healthcare landscape and the greater business community through his work as a member of the Business Roundtable, the Business Council, and many industry groups. He currently sits on the boards of Apple, IBM, JPMorgan Chase, and the Travis Manion Foundation, as well as the Wharton School of the University of Pennsylvania Board of Advisors. “I am delighted to welcome Alex to Neurotech’s Board of Directors,” said Jim Mazzo, Neurotech’s Executive Chairman. “As a visionary in patient focused healthcare, his expertise and enthusiasm for innovative technology will greatly enrich Neurotech’s mission to revolutionize treatments for various ocular diseases using our encapsulated cell therapy.” Mr. Gorsky said, “I am honored to join Neurotech’s board and look forward to using my experience to help the company navigate in a rapidly evolving environment. I am inspired by the Lowy family’s long-term commitment. This unique scientific approach and novel technology for the treatment of chronic eye diseases has the potential to provide access to important health options for patients around the world.” About Macular telangiectasia type 2 Macular telangiectasia type 2 (MacTel), or idiopathic juxtafoveal macular telangiectasia type 2, is a rare neurodegenerative disease with characteristic alterations of the retinal vasculature and localized retinal degeneration.1 MacTel typically affects both eyes and causes a gradual deterioration in central vision. About NT-501 Implant Designed to be implanted into the vitreous cavity of the eye, the investigational NT-501 implant is a tiny hollow cylindrical membrane which encapsulates human epithelial cells genetically engineered to produce ciliary neurotropic factor (CNTF) continuously, a protein now clinically validated in Phase 3 clinical trials to slow the progression of MacTel. About Encapsulated Cell Therapy Encapsulated Cell Therapy (ECT) is an investigational first-in-class, platform technology that promotes continuous production of therapeutic proteins to the eye with the potential to treat a broad array of ocular diseases. It utilizes a proprietary, well-characterized retinal pigment epithelial cell line that is genetically engineered to produce therapeutically active biologics. The cells are encapsulated in a semi-permeable membrane that allows for selective passage of therapeutic proteins. The ECT platform is inserted during a single outpatient surgical procedure through a small scleral incision, and can also be removed through the same incision, if desired. ECT has the potential to address the current limitations of intraocular drug delivery by allowing for and ensuring patient compliance, while reducing the treatment burden with one surgical procedure that can deliver the drug for at least 2 years. About Neurotech Pharmaceuticals, Inc. Neurotech Pharmaceuticals, Inc. is a private clinical stage biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, Encapsulated Cell Therapy (ECT), enables continuous production of therapeutic proteins to the eye. Neurotech is currently studying in the clinic ECT candidates to treat Macular telangiectasia type 2 and glaucoma. To learn more, visit . 1. Charbel Issa P, Gillies MC, Chew EY, Heeren TFC, Bird AC, Peto T, Holz FG, Scholl HPN (2013) Macular Telangiectasia Type 2. Prog. Retin. Eye Res. 34: 49-77.

细胞疗法高管变更临床3期

2023-01-10

·BioSpace

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

CUMBERLAND, R.I.--(BUSINESS WIRE)-- Neurotech Pharmaceuticals, Inc., a clinical stage biotech company, today announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eyecare experience across both rare disease and specialty markets. This press release features multimedia. View the full release here: Scott Hunter Joins Neurotech Pharmaceuticals as Chief Commercial Officer (Photo: Business Wire) “Scott’s appointment as the Company’s first Chief Commercial Officer marks an important milestone for Neurotech. Scott will be instrumental in helping us develop the commercial strategy and establish our commercial infrastructure,” said Richard Small, Chief Executive Officer of Neurotech. “His proven success of bringing products to market that address unmet needs is a perfect fit with our vision and culture, which is dedicated to slowing disease progression while helping patients maintain vision and quality of life.” “I am extremely excited to join the Neurotech team and build the commercial organization” stated Scott Hunter. “Starting with science behind NT-501, I believe Neurotech can drastically change the management of sight-threatening retinal conditions such as MacTel.” Scott joins Neurotech with a demonstrated track record in global rare and specialty eyecare experience. He most recently worked at Novartis where he was the Global Marketing Head for Luxturna (voretigene neparvovec-rzyl), responsible for advancing the global strategy for the first commercially approved ocular gene therapy. Before Novartis, Scott was at Shire, where he was instrumental in the build-out of the U.S. ophthalmics franchise and launch of Xiidra, culminating in the divestiture to Novartis for up to $5.3 billion. Prior he spent 12 years at Bausch & Lomb, where he held roles of increasing responsibility across research and development (R&D) and marketing. Scott earned his M.S. in Pharmacoeconomics from the University of Florida and his M.B.A. from the University of Tampa after completing his B.S. in Biology at the University of South Florida. About Macular telangiectasia type 2 Macular telangiectasia type 2 (MacTel), or idiopathic juxtafoveal macular telangiectasia type 2, is a rare neurodegenerative disease with characteristic alterations of the retinal vasculature and localized retinal degeneration.1 MacTel typically affects both eyes and causes a gradual deterioration in central vision. About NT-501 Implant Designed to be implanted into the vitreous cavity of the eye, the investigational NT-501 implant is a tiny hollow cylindrical membrane which encapsulates human epithelial cells genetically engineered to produce ciliary neurotropic factor (CNTF) continuously, a protein now clinically validated in Phase 3 clinical trials to slow the progression of MacTel. About Encapsulated Cell Therapy Encapsulated Cell Therapy (ECT) is an investigational first-in-class, platform technology that promotes continuous production of therapeutic proteins to the eye with the potential to treat a broad array of ocular diseases. It utilizes a proprietary, well-characterized retinal pigment epithelial cell line that has been genetically engineered to produce therapeutically active biologics. The cells are encapsulated in a semi-permeable membrane that allows for selective passage of therapeutic proteins. The ECT platform is inserted during a single outpatient surgical procedure through a small scleral incision, and can also be removed through the same incision, if desired. ECT has the potential to address the current limitations of intraocular drug delivery by allowing for and ensuring patient compliance and reducing treatment burden with one surgical procedure that can deliver drug for at least 2 years. About Neurotech Pharmaceuticals, Inc. Neurotech Pharmaceuticals, Inc. is a private clinical stage biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, ECT, enables continuous production of therapeutic proteins to the eye. Neurotech is currently studying in the clinic ECT candidates to treat Macular telangiectasia type 2 and glaucoma. To learn more, visit . Charbel Issa P, Gillies MC, Chew EY, Heeren TFC, Bird AC, Peto T, Holz FG, Scholl HPN (2013) Macular Telangiectasia Type 2. Prog. Retin. Eye Res. 34: 49-77.

临床3期细胞疗法高管变更基因疗法

2022-12-04

·医药观澜

超10款新药3期临床达主要终点，来自辉瑞、和黄医药等公司

▎药明康德内容团队报道公开资料显示，在刚刚结束的11月份，又有多款创新药在3期临床试验中达到主要研究终点。这些药物包括RSV候选疫苗、靶向性放射疗法、血红细胞成熟剂、封装细胞疗法、抗Claudin18.2抗体、NMDA受体拮抗剂等等。本文将结合公开信息分享其中10款创新药的临床试验进展信息，看看它们将有望给哪些患者带来新的治疗选择？（按公司宣布时间先后排序）图片来源：123RF辉瑞：RSVpreF作用机制：RSV候选疫苗适应症：RSV感染11月1日，辉瑞（Pfizer）宣布其在研双价呼吸道合胞病毒（RSV）候选疫苗RSVpreF于临床3期试验中获得积极顶线分析结果。数据分析显示，试验达成两个主要终点的其中一项，即疫苗避免婴孩出生后90天内感染严重性MA-LRTI的保护力达81.8%，避免婴孩在出生后6个月的追踪期间感染严重性MA-LRTI的保护力达69.4%。同时，该疫苗显示出良好的耐受性。辉瑞预计在2022年年底向美国FDA递交生物制品许可申请（BLA）。Actinium公司：Iomab-B作用机制：靶向性放射疗法适应症：急性髓系白血病（AML）11月1日，Actinium公司宣布其候选药物Iomab-B在关键性3期临床试验中取得积极顶线结果。lomab-B是一款靶向性放射疗法，其药物分子设计将单克隆抗体apamistama与放射性同位素碘-131相连接，并以细胞表面的CD45作为靶点。当Iomab-B附着于靶细胞上时便会释放出能量，可以破坏AML患者体内的癌细胞并消除他们自身的骨髓。本次公布的3期试验SIERRA数据显示，研究达到了主要终点，与对照组相比，在骨髓移植后，更多接受Iomab-B治疗的患者完全缓解时间持续6个月以上。Actinium公司计划向FDA递交该候选药物的生物制品许可申请，为55岁以上无法使用现有疗法进行骨髓移植的AML患者提供治疗选择。百时美施贵宝：luspatercept作用机制：血红细胞成熟剂适应症：MDS患者贫血症状11月1日，百时美施贵宝（BMS）宣布其血红细胞成熟剂luspatercept于3期临床试验中达成主要终点。Luspatercept是一种可溶性融合蛋白，它能够作为TGF-β的配体陷阱（ligand trap），防止TGF-β激活Smad2/3信号通路，进而促进晚期血红细胞的分化和成熟，以减轻患者定期血红细胞输注的负担。该药此前已获FDA批准用于治疗需要定期输注血红细胞的β地中海贫血成人患者的贫血症。本次公布的3期临床试验旨在评估luspatercept与血红细胞生成刺激剂相较，在治疗极低、低或中度风险成人骨髓增生异常综合征（MDS）患者贫血症状方面的疗效与安全性。试验的主要终点为维持12周血红细胞输注独立性，并达成平均血红蛋白水平≥1.5 g/dL的上升。预定的中期分析数据显示，该试验达到主要终点，且luspatercept展现的安全性与以往试验一致，没有发现新的安全性问题。Nicox公司：NCX470（0.1%）作用机制：新型化学药物适应症：开角型青光眼或高眼压症11月1日，Nicox公司宣布其在研眼药水NCX470（0.1%）在3期临床试验的顶线分析中达成主要终点。NCX470是一种创新的化学药物，旨在释放比马前列素（一种FDA批淮的前列腺素类似物）及一氧化氮（NO）。通过将一氧化氮介导的药效与比马前列素联合，该药可以激活眼睛的原生性及继生性房水流出，这种双重作用机制有助于提高眼内压的降低效果。本次公布的3期临床数据显示，在治疗开角型青光眼或高眼压症患者上，NCX470与标准治疗药物相较达成非劣效性。值得一提的是，欧康维视生物拥有该药在大中华区、韩国及东南亚另外12个国家和地区的独家开发和商业化权利。Neurotech公司：NT-501作用机制：封装细胞疗法适应症：２型黄斑毛细管扩张症11月2日，Neurotech公司宣布其在研封装细胞疗法NT-501在治疗２型黄斑毛细管扩张症的两项３期临床试验中取得积极结果。NT-501是一种可以植入眼睛玻璃体内的微小中空圆柱形半透膜装置，装载着通过基因工程可以持续分泌睫状神经营养因子的人类上皮细胞。２型黄斑毛细管扩张症是一种罕见的神经退行性疾病。本次公布的3期临床试验数据显示：接受两种治疗方案的2型黄斑毛细管扩张症患者的疾病进展速率均有所降低，其中方案A的减少为56.4%，方案B则减少29.2%；在两种方案中，NT-501均表现出良好的安全性和耐受性。勃林格殷格翰/礼来：恩格列净作用机制：SGLT2抑制剂适应症：慢性肾病11月5日，勃林格殷格翰（Boehringer Ingelheim）与礼来（Eli Lilly and Company）联合宣布，双方合作开发的恩格列净在一项3期临床试验中达到主要终点。恩格列净是一款每日口服一次、高选择性的钠葡萄糖协同转运蛋白2（SGLT2）抑制剂。本次公布的3期临床试验EMPA-KIDNEY旨在评估恩格列净在改善肾脏疾病进展与心血管死亡风险方面的疗效。试验数据显示，与安慰剂组相比，恩格列净能够将患者的肾脏疾病进展或心血管死亡风险降低28%，并将患者的住院风险降低了14%。和黄医药：呋喹替尼作用机制：VEGFR抑制剂适应症：胃癌11月14日，和黄医药宣布呋喹替尼二线治疗胃癌的中国3期研究FRUTIGA取得阳性顶线结果。呋喹替尼是一种高选择性、强效的口服血管内皮生长因子受体（VEGFR）-1、2及3抑制剂，此前已在中国获批治疗转移性结直肠癌患者。本次公布的3期临床研究旨在评估呋喹替尼和紫杉醇联合疗法二线治疗晚期胃癌或胃食管结合部腺癌患者的效果和安全性。试验数据显示，FRUTIGA研究取得了阳性结果，达到了其中一个主要终点，即患者的无进展生存期（PFS）取得具有统计学意义的显著改善。维昇药业：隆培促生长素作用机制：长效生长激素适应症：儿童生长激素缺乏症11月17日，维昇药业宣布其隆培促生长素在中国的3期关键临床试验中达到主要终点。隆培促生长素是一种每周给药一次且释放未经修饰生长激素的前药，已在欧盟和美国获批上市。本次公布的数据显示：在治疗52周后，隆培促生长素的年化生长速率（AHV）为10.66厘米/年，优于短效（每日注射）人生长激素组的9.75厘米/年；隆培促生长素组在第52周时的身高标准偏差评分较基线增加了1.01，也优于短效（每日注射）人生长激素组的0.83。而且，从第13周开始，隆培促生长素组身高标准偏差评分改善更明显。杨森：esketamine鼻喷雾剂作用机制：NMDA受体拮抗剂适应症：难治性抑郁症11月23日，强生（Johnson & Johnson）旗下杨森（Janssen）公司宣布，其开发的esketamine鼻喷雾剂在针对成人难治性抑郁症（TRD）患者的3b期临床试验ESCAPE-TRD中达到主要研究终点。该药是一款非选择性、非竞争性NMDA受体拮抗剂，最早于2019年获得美国FDA批准上市，是30年以来第一款采用新作用机制治疗抑郁症的药物。本次公布的3b期试验数据显示，该研究达到了其主要终点：与喹硫平缓释片组相比，esketamine鼻喷雾剂在第8周实现缓解方面具有更好的疗效（27.1% vs. 17.6%）。此外，在实现第8周的主要终点后，两组的缓解率继续增加。与对照组相比，esketamine鼻喷雾剂组在第32周时达到缓解的患者比例明显更高（55% vs. 37%）。安斯泰来：zolbetuximab作用机制：抗Claudin18.2抗体适应症：胃癌11月17日，安斯泰来（Astellas Pharma）宣布，其开发的靶向Claudin18.2的在研抗体zolbetuximab在一项针对胃癌的3期临床试验中达到主要终点。这是一项名为SPOTLIGHT的3期临床试验，旨在评估zolbetuximab与化疗联用一线治疗局部晚期不可切除或转移性胃癌的疗效和安全性。试验结果显示，与对照组相比，zolbetuximab联合化疗可显著提高患者的无进展生存期（PFS）和总生存期（OS）。值得一提的是，zolbetuximab也是首个进入3期临床试验阶段的Claudin18.2靶向疗法，本次3期临床试验的积极结果也是Claudin18.2靶向疗法研究领域的一个重要进展。Axsome公司：AXS-05作用机制：NMDA受体拮抗剂适应症：阿尔茨海默病11月29日，Axsome Therapeutics宣布其在研疗法AXS-05（右美沙芬+安非他酮）在一项针对阿尔茨海默病（AD）的3期临床试验中达到主要终点与次要终点。AXS-05是一种新型口服在研N-甲基-D-天冬氨酸（NMDA）受体拮抗剂，具有多种作用机制，拟开发用于治疗重度抑郁症和其它中枢神经系统（CNS）疾病。该药已获得FDA授予突破性疗法认定，用于治疗重度抑郁症和阿尔兹海默病激越症状。本次公布的数据显示，AXS-05能显著地延缓和避免阿尔茨海默病患者激越症状的复发。除了上述产品，还有一些创新药也于近期宣布在3期临床中取得积极结果。限于篇幅，本文不再一一介绍。希望它们在后续的研究中顺利进行，早日获批，造福广大病患。参考资料（可上下滑动查看） [1]隆培促生长素中国3期临床试验52周数据首发为目前证实唯一优效于生长激素日制剂的长效生长激素. Retrieved Nov 17 , 2022. From https://mp.weixin.qq.com/s/cVZQyNRru29CvTQDCbAXAQ[2]SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1. Retrieved Nov 23 , 2022. From https://www.businesswire.com/news/home/20221123005062/en[3] Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers. Retrieved November 17, 2022, from https://www.astellas.com/en/news/26821[4] Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel. Retrieved November 2, 2022, from https://www.neurotechpharmaceuticals.com/post/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-mactel[5] Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease. Retrieved November 4, 2022 from https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/full-data-chronic-kidney-disease-trial-efficacy[6] Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate. Retrieved November 1, 2022 from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global[10]和黄医药宣布呋喹替尼二线治疗胃癌的FRUTIGA中国III期研究取得阳性顶线结果. Retrieved Nov 14 , 2022. From https://mp.weixin.qq.com/s/GRmvRWlhRjRytiqWsVMPZA[11] axsome therapeutics announces axs-05 achieves primary endpoint in the accord phase 3 trial in alzheimer’s disease agitation. Retrieved November 28, 2022 from https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-3本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期放射疗法疫苗临床结果

100 项与 NT-501 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
视网膜毛细血管扩张	无进展	英国更多	Neurotech USA, Inc. 更多
色觉障碍	无进展	美国更多	National Eye Institute 更多
视神经疾病	无进展	美国更多	Neurotech USA, Inc. 更多
青光眼	无进展	美国更多	Neurotech USA, Inc. 更多
视网膜色素变性	无进展	美国更多	Neurotech USA, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2023	N/A	-	-	NT-501 Implant	積觸築顧艱積鏇廠鑰顧(鏇衊積鹽鬱願繭簾憲鬱) = 餘築構廠網積積壓齋獵艱獵積選窪鑰衊淵願鹹 (繭窪窪鹹觸製淵觸鑰糧 )	-	2023-04-23
NCT03316300 (Protocol A, Biospace) 人工标引	临床3期	2型黄斑毛细血管扩张症	115	NT-501	網選鬱觸網積顧鹹窪網(鬱醖構壓願顧獵餘窪鏇) = 鹽積淵繭觸鑰窪夢鹽獵膚構淵範鑰製構夢觸膚 (醖齋膚鬱築醖築範積願 )	积极	2022-11-02
				Sham Procedure	-
Biospace 人工标引	临床3期	2型黄斑毛细血管扩张症	113	NT-501	選壓選蓋繭壓鹽醖觸壓(齋鬱襯製夢製艱衊構遞) = 膚製醖選餘鬱繭廠壓膚網網顧願願獵願網窪鹹 (淵膚繭顧範鑰壓網願積 ) 更多	积极	2022-11-02
				Sham Procedure	-